Defining REMS Success An Unanswered Question For Daiichi's Pexidartinib

 
• By Derrick Gingery
Liver cancer, CT scan upper abdomen.
FDA wants to collect long-term data on pexidartinib's liver toxicity risks as part of a Risk Evaluation and Mitigation Strategy. • Source: Shutterstock

More from Drug Safety

More from Pink Sheet